Baxter International (NYSE:BAX) Releases Q3 2025 Earnings Guidance

Key Points

• Baxter International has updated its Q3 2025 earnings guidance with an expected EPS of 0.580-0.620, lower than the consensus estimate of 0.646, while revenue guidance remains at $2.9 billion.
• The company's stock has seen a significant decline of 18.0%, opening at $23.00 per share, with a current market capitalization of $11.80 billion.
• Baxter recently announced a dividend of $0.17 per share, reflecting an annualized dividend yield of 2.96%, despite a negative payout ratio of -61.82%.

Baxter International (NYSE:BAX - Get Free Report) updated its third quarter 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.580-0.620 for the period, compared to the consensus estimate of 0.646. The company issued revenue guidance of $2.9 billion-$2.9 billion, compared to the consensus revenue estimate of $2.9 billion. Baxter International also updated its FY 2025 guidance to 2.420-2.520 EPS.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a research note on Tuesday, July 15th. Wells Fargo & Company cut their price objective on shares of Baxter International from $33.00 to $24.00 and set an "equal weight" rating for the company in a research report on Friday. Evercore ISI decreased their target price on Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Citigroup lowered their target price on Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 9th. Finally, Wall Street Zen lowered Baxter International from a "buy" rating to a "hold" rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $33.13.

Baxter International Price Performance

NYSE:BAX traded up $0.21 on Friday, reaching $21.97. 22,646,910 shares of the company's stock traded hands, compared to its average volume of 7,544,769. The stock has a 50-day simple moving average of $29.52 and a 200-day simple moving average of $31.03. Baxter International has a 12 month low of $21.33 and a 12 month high of $40.49. The firm has a market cap of $11.27 billion, a PE ratio of -73.23, a P/E/G ratio of 0.65 and a beta of 0.59. The company has a quick ratio of 1.40, a current ratio of 2.02 and a debt-to-equity ratio of 1.33.

Baxter International (NYSE:BAX - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). Baxter International had a positive return on equity of 16.93% and a negative net margin of 1.42%. The business had revenue of $2.81 billion during the quarter, compared to analysts' expectations of $2.82 billion. During the same period in the prior year, the firm posted $0.68 earnings per share. The firm's revenue for the quarter was up 4.3% on a year-over-year basis. Equities research analysts forecast that Baxter International will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, August 29th. Baxter International's dividend payout ratio (DPR) is presently -226.67%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.